Skip to content

Efficacy and safety of tacrolimus in the treatment of children with allergic purpura nephritis

Efficacy and safety of tacrolimus in the treatment of children with allergic purpura nephritis

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055323
Enrollment
Unknown
Registered
2022-01-07
Start date
2016-08-01
Completion date
Unknown
Last updated
2023-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic purpuric nephritis in children

Interventions

Sponsors

Lanzhou University Second Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
4 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Children with a clear diagnosis of allergic purpura nephritis, 24-hour urine protein quantitative >= 0.75g; 2. The pathological ISKDC grades are grade II, grade III and above pathological types; 3. Children aged 4-18 years.

Exclusion criteria

Exclusion criteria: 1. Patients of primary IgA nephropathy, primary nephrotic syndrome, lupus nephritis, hepatitis B virus-related nephritis, and post-streptococcal glomerulonephritis; 2. Patients with HSPN combined with organic heart disease or central nervous system disease, patients with essential hypertension, patients with vision and visual abnormalities, patients with diabetes, patients with tuberculosis and EB virus infection and other infectious diseases; 3. Those with known contraindications or allergies to the drugs used; 4. Those with poor compliance; 5. Those with drug malabsorption.

Design outcomes

Primary

MeasureTime frame
hematuria;

Secondary

MeasureTime frame
proteinuria;demographic data;

Countries

China

Contacts

Public ContactYang Yonghong
yhyangyh@126.com+86 18919969968

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026